

Anna C Bibby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1142618/publications.pdf>

Version: 2024-02-01

17
papers

766
citations

1039406

9
h-index

887659

17
g-index

20
all docs

20
docs citations

20
times ranked

833
citing authors

#	ARTICLE	IF	CITATIONS
1	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. <i>European Respiratory Review</i> , 2016, 25, 472-486.	3.0	225
2	Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. <i>New England Journal of Medicine</i> , 2018, 378, 1313-1322.	13.9	183
3	ERS/EACTS statement on the management of malignant pleural effusions. <i>European Respiratory Journal</i> , 2018, 52, 1800349.	3.1	179
4	Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection. <i>Chest</i> , 2015, 148, 235-241.	0.4	34
5	Pleural biopsies in undiagnosed pleural effusions; Abrams vs image-guided vs thoracoscopic biopsies. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 392-398.	1.2	32
6	Current treatments and trials in malignant pleural mesothelioma. <i>Clinical Respiratory Journal</i> , 2018, 12, 2161-2169.	0.6	21
7	The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1273-1279.	1.5	20
8	What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. <i>BMJ Open</i> , 2016, 6, e012092.	0.8	15
9	Nutritional management in chyle leaks and chylous effusions. <i>British Journal of Community Nursing</i> , 2014, 19, S6-S8.	0.2	14
10	Commentary: considerations for using the "Trials within Cohorts"™ design in a clinical trial of an investigational medicinal product. <i>Trials</i> , 2018, 19, 18.	0.7	9
11	Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study. <i>BMC Palliative Care</i> , 2017, 16, 71.	0.8	8
12	Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review. <i>Lung Cancer</i> , 2018, 122, 249-256.	0.9	6
13	Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?. <i>Chest</i> , 2021, 160, 1915-1924.	0.4	6
14	Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma. <i>BMC Pulmonary Medicine</i> , 2022, 22, 173.	0.8	5
15	Medical and oncological management of malignant mesothelioma. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2015, 76, 384-389.	0.2	4
16	The priorities of people with mesothelioma and their carers: A qualitative interview study of trial participation and treatment decisions. <i>European Journal of Oncology Nursing</i> , 2022, 57, 102111.	0.9	3
17	Is pleural infection associated with longer survival in mesothelioma? A population-based cohort study using data from Hospital Episode Statistics. <i>Cancer Epidemiology</i> , 2019, 59, 75-82.	0.8	1